Clinical Trial Application for Innovative Drug SAL0145 Injection Accepted
January 8, 2026
Source: drugdu
33
On January 7, Salubris (002294.SZ) announced that the clinical trial application (IND) for its self-developed innovative drug, SAL0145 Injection, has been formally accepted by the National Medical Products Administration (NMPA).
According to relevant regulations, if no negative or questioning feedback is received from the Center for Drug Evaluation (CDE) within 60 days, the applicant may proceed with the clinical trials as per the submitted protocol.
SAL0145 is designed as a treatment for metabolic dysfunction-associated steatohepatitis (MASH). MASH is an advanced form of metabolic dysfunction-associated steatotic liver disease (MASLD), a condition that affects approximately 30% of the adult population worldwide.
In terms of financial performance, Salubris reported a revenue of 3.241 billion yuan and a net profit attributable to shareholders of 581 million yuan for the first three quarters of 2025.
https://finance.eastmoney.com/a/202601073611609222.html
By editor
Copyright©2026 Ddu. All rights reserved.
Read more on
- Betamethasone Sodium Phosphate Injection Approved January 9, 2026
- OpenAI releases two AI products in the healthcare field. January 9, 2026
- Say goodbye to lifelong medication? Hepatitis B patients may be entering an era of “functional cure”. January 9, 2026
- Xuantai Pharmaceutical’s “Isaconazole Sulfate for Injection” has been approved for marketing by the National Medical Products Administration, enriching new options for antifungal treatment January 9, 2026
- Fosun Pharma resubmits its application for listing of Furuitinib January 9, 2026
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
